Is Citius Oncology, Inc. profitable?

Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.

What is Citius Oncology, Inc.'s earnings per share?

Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.

Where does Citius Oncology, Inc.'s income statement data come from?

Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Citius Oncology, Inc. CTOR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q2 '26	Q1 '26	Q4 '25	Q3 '25	Q2 '25
Total revenue	$1.67M-57.7%	$3.94M—	——	——	——
Total cost of revenue	$328.88K-58.3%	$789.21K—	——	——	——
Gross profit	$1.34M-57.6%	$3.15M—	——	——	——
Gross margin	80.3%+0.3pp	80%—	——	——	——
Research and development	$1.08M+6.0%	$1.02M-5.4%	$1.08M+14.7%	$938.28K-70.1%	$3.14M+148%
General and administrative	$23.63M+726%	$2.86M+114%	$1.34M-28.9%	$1.88M-16.1%	$2.24M-32.5%
Compensation and benefits	$3.53M-10.9%	$3.96M+72.1%	$2.3M+8.1%	$2.13M+1.8%	$2.09M+15.5%
Other operating expenses	$29.95M+256%	$8.41M+78.4%	$4.71M-4.7%	$4.94M-33.8%	$7.47M+16.8%
Total operating expenses	$29.95M+256%	$8.41M+78.4%	$4.71M-4.7%	$4.94M-33.8%	$7.47M+16.8%
Operating income	-$28.61M-445%	-$5.25M-11.5%	-$4.71M+4.7%	-$4.94M+33.8%	-$7.47M-16.8%
Operating margin	-1,716.2%-1,583pp	-133.2%—	——	——	——
Interest expense	$33.03K-27.9%	$45.84K-20.0%	$57.28K-64.4%	$160.76K—	——
Interest income	$43.72K+54.6%	$28.29K+211%	$9.09K0.0%	$9.09K0.0%	$9.09K0.0%
Other income (expense), net	$1.77M+10,199%	-$17.55K+61.3%	-$45.41K0.0%	-$45.41K0.0%	-$45.41K0.0%
Income before income taxes	-$26.84M-409%	-$5.27M-11.4%	-$4.73M+7.3%	-$5.11M+31.7%	-$7.47M-16.8%
Income tax expense	-$231.21K-188%	$264.24K0.0%	$264.24K0.0%	$264.24K0.0%	$264.24K0.0%
Net income	-$26.61M-381%	-$5.53M-10.8%	-$5M+7.0%	-$5.37M+30.6%	-$7.74M-16.2%
Net margin	-1,596%-1,456pp	-140.3%—	——	——	——
Diluted earnings per share	-$0.27-350%	-$0.060.0%	-$0.06+25.0%	-$0.08+27.3%	-$0.11-22.2%
Basic earnings per share	-$0.27-350%	-$0.060.0%	-$0.06+25.0%	-$0.08+27.3%	-$0.11-22.2%
Weighted-average shares, diluted	100M+14.4%	87.5M+19.4%	73.3M+2.4%	71.6M0.0%	71.6M0.0%
Weighted-average shares, basic	100M+14.4%	87.5M+19.4%	73.3M+2.4%	71.6M0.0%	71.6M0.0%
Amortization Of Inprocess Research And Development	$1.72M+200%	$573.44K—	——	——	——
Other expenses	$27.94K0.0%	$27.94K0.0%	$27.94K0.0%	$27.94K-8.0%	$30.37K0.0%
Gain On Sale Of New Jersey Net Operating Losses	$1.76M—	——	——	——	——
Adjustments To Additional Paid In Capital December2025Offering Costs	-$62.77K—	——	——	——	——
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	$3.53M-10.9%	$3.96M+72.1%	$2.3M+8.1%	$2.13M+1.8%	$2.09M+15.5%
Capital Contribution Of Due To Related Party By Parent	——	——	——	——	——
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	-$4.66M-238%	$3.37M+244%	$981.2K0.0%	$981.2K0.0%	$981.2K0.0%
Commercial Sales Milestones	——	$300M—	——	——	——
December2025Sale Of Common Stock And Prefunded Warrants Net Of Costs	——	$2.87M—	——	——	——
Deferred taxes	——	$264.24K0.0%	$264.24K0.0%	$264.24K0.0%	$264.24K0.0%
Development Milestone Payments	——	$70M+64.7%	$42.5M—	——	——
Effective tax rates	——	——	$0.04+300%	$0.010.0%	$0.010.0%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	26.2%—	——	——
Foreign operations	——	——	-7.1%—	——	——
Effective Income Tax Rate Reconciliation Permanent Differences	——	——	6.3%—	——	——
State income taxes – net of federal income tax benefit	——	——	-21%—	——	——
Fair Value Adjustment Of Warrants	——	——	$905K—	——	——
Fair Value Of Common Stock Grant Date	——	——	$20.3M—	——	——
Federal Net Operating Loss Carryforward	——	——	$11.79M0.0%	$11.79M0.0%	$11.79M0.0%
Federal Research And Development	——	——	$395.25K0.0%	$395.25K0.0%	$395.25K0.0%
Gross Product Revenue	$2M-58.9%	$4.88M—	——	——	——
Grosstonet Adjustments	$336.46K-64.0%	$934.61K—	——	——	——
In Process Research And Development Amount	——	——	$18.35M0.0%	$18.35M0.0%	$18.35M0.0%
In Process Research And Development Initial Payments	——	——	$10M0.0%	$10M0.0%	$10M0.0%
Increase (Decrease) in Accounts Payable, Trade	-$1.56M+43.9%	-$2.79M-161%	$4.57M+361%	$991.11K-45.0%	$1.8M-16.7%
Increase (Decrease) in Accounts Receivable	——	$4.05M—	——	——	——
Accrued liabilities	$19.54M+4,489%	$425.79K—	——	——	$2.49M-60.0%
Increase (decrease) in due to related parties	-$3.27M-265%	$1.98M-3.3%	$2.05M-18.8%	$2.52M+23.3%	$2.05M-11.4%
Increase (Decrease) in Inventories	$20.25K-94.3%	$352.65K-90.5%	$3.71M+98.4%	$1.87M+95.2%	$957.88K-84.3%
Increase (Decrease) in Prepaid Expense	——	$1.83M—	——	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	——	$14.46K-69.1%	$46.85K0.0%	$46.85K0.0%	$46.85K0.0%
IP Ramp D Milestones Included In License Payable	——	——	——	——	——
Issuance Of Common Stock In July2025Registered Direct Offering Net Of Costs	——	——	$363.25K0.0%	$363.25K0.0%	$363.25K0.0%
Issuance Of Common Stock In September2025Registered Direct Offering Net Of Costs	——	——	$345.04K0.0%	$345.04K0.0%	$345.04K0.0%
Long-term material purchase obligations	——	$16.2M—	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——	$15.13M+299%	$3.79M0.0%	$3.79M0.0%	$3.79M0.0%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$600K+86.4%	-$4.4M-206%	-$1.44M0.0%	-$1.44M0.0%	-$1.44M0.0%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$3.83M+47.9%	-$7.35M-436%	-$1.37M0.0%	-$1.37M0.0%	-$1.37M0.0%
Net Proceeds From Offering	——	——	$7.55M—	——	——
Noncash Merger Related Costs	——	$2.75M—	——	——	——
Number of operating segments	——	——	100%—	——	——
Number of reportable segments	——	——	100%—	——	——
Other General and Administrative Expense	$567.94K+14.1%	$497.94K0.0%	$497.93K-12.3%	$567.94K0.0%	$567.94K0.0%
Outstanding Remaining Balance Of Milestone	——	$18.25M+270%	$4.94M0.0%	$4.94M0.0%	$4.94M0.0%
Payment For Other Invoice And Accumulated Interest	——	——	$1.62M—	——	——
Payment On Expenses Of Placement Agent Fee	——	——	$125K—	——	——
Payments to acquire in process research and development	——	$40M—	——	——	——
Payments to Acquire Intangible Assets	$600K-86.4%	$4.4M+206%	$1.44M0.0%	$1.44M0.0%	$1.44M0.0%
Prepaid Manufacturing Transferred To Inventory	——	——	$342.18K0.0%	$342.18K0.0%	$342.18K0.0%
Proceeds from debt financing, net of issuance costs	——	——	——	——	——
Proceeds from Issuance of Common Stock	——	$15.13M-0.3%	$15.17M—	——	——
Reimburse Amount	——	$2.65M—	——	——	——
Related Transaction Costs	——	$2.36M+300%	$589.7K0.0%	$589.7K0.0%	$589.7K0.0%
Repayments of Notes Payable	——	——	$20M—	——	——
Stock-based compensation	$3.53M-10.9%	$3.96M+72.1%	$2.3M+8.1%	$2.13M+1.8%	$2.09M+15.5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period	——	——	400K—	——	——
Forfeited or expired (in shares)	——	——	$2.02—	——	——
Stock Issued During Period Shares Proceeds From Exercise Of Prefunded Warrantsin Shares	8.2M—	——	——	——	——
Stock Issued During Period Value Common Stock In July2025Registered Direct Offering	——	——	$1.89M0.0%	$1.89M0.0%	$1.89M0.0%
Stock Issued During Period Value Common Stock In September2025Registered Direct Offering	——	——	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%
Stock Issued During Period Value December2025Sale Of Common Stock And Prefunded Warrants Net Of Costs	——	$15.13M—	——	——	——
Stock Issued During Period Value Merger Net Of Transaction Costs	——	——	——	——	——
Stock Issued During Period Value Proceeds From Exercise Of Prefunded Warrants	$818—	——	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	——	$1.92M0.0%	$1.92M0.0%	$1.92M0.0%
EBIT	-$28.61M-445%	-$5.25M-11.5%	-$4.71M+4.7%	-$4.94M+33.8%	-$7.47M-16.8%
EBIT	-$28.61M-445%	-$5.25M-11.5%	-$4.71M+4.7%	-$4.94M+33.8%	-$7.47M-16.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Citius Oncology, Inc. profitable?: Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.
What is Citius Oncology, Inc.'s earnings per share?: Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.
Where does Citius Oncology, Inc.'s income statement data come from?: Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.